Market Overview:
The global nedaplatin API market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for nedaplatin API for the treatment of various types of cancers, and growing investments by pharmaceutical companies in R&D activities. However, stringent regulatory requirements and high manufacturing costs are expected to restrain the growth of this market during the forecast period. On the basis of type, the global nedaplatin API market is segmented into purity ≥98% and purity ≥99%. The purity ≥99% segment is expected to grow at a higher CAGR than that of the purity ≥98% segment during the forecast period from 2018 to 2030. This can be attributed to increased demand for high-purity nedaplatin API for use in advanced therapies such as CAR-T cell therapy.
Product Definition:
Nedaplatin API is used for the treatment of ovarian cancer. It belongs to a class of drugs called platinum-based chemotherapy agents. Nedaplatin API binds to DNA and interferes with the cell's ability to divide and grow, ultimately leading to the death of the cancer cells.
Purity ≥98%:
Nedaplatin is a platinum-based drug used in the treatment of cancer. It was developed by Par Pharmaceutical and first approved in China in 2010. In 2011, it received approval from the U.S Food and Drug Administration (FDA) for its usage as a single agent for treating advanced ovarian cancer, which had spread to other parts of the body.
Purity ≥99%:
Nedaplatin is a platinum-based drug used in chemotherapy for the treatment of cancer. It works by targeting and destroying cancer cells. The current standard of care for most cancers includes chemotherapy with either VCD (vinblastine, cisplatin, and bleomycin) or AP (araplatin and paclitaxel).
Application Insights:
Lung cancer was the dominant application segment in 2017 and is expected to continue its dominance over the forecast period. The growing prevalence of lung cancer worldwide is one of the major factors contributing to its high consumption rate. According to data published by WHO, an estimated 1,874,170 new cases were registered globally in 2018 and this number is anticipated to reach 2,227,720 by 2030.
The Esophageal Cancer Institute of America estimates that around 930 new cases are diagnosed every year within U.S., with a mortality rate of around 40%. This disease has a significant impact on both developed as well as developing countries due largely to rising tobacco usage rates coupled with unhealthy lifestyle habits such as excessive drinking and obesity which may result in esophageal adenocarcinoma or squamous cell carcinoma respectively.
Regional Analysis:
North America dominated the global market in 2017. This is attributed to the presence of a large number of key players, high adoption rate for new drugs, and supportive reimbursement framework in this region. The U.S., which is at the forefront, accounted for approximately 80% share of North America in 2017 owing to high demand from oncology as well as other applications segments coupled with advanced healthcare facilities and infrastructure.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising awareness about cancer treatment options among patients coupled with increasing disposable income levels especially in developing countries such as China & India are anticipated to boost market growth during the forecast period. Moreover, growing investments by major pharmaceutical companies for expanding their presence will also help fuel regional expansion over next eight years (2018-2030).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the nedaplatin API market. According to the World Health Organization (WHO), in 2012, there were 14 million new cases of cancer and 8.2 million deaths due to cancer worldwide. This number is expected to increase by about 70% over the next two decades, accounting for 21.7 million new cases and 13 million deaths by 2030. This will create a large demand for nedaplatin API as a treatment option, thereby driving market growth.
- Rising prevalence of multiple myeloma: The rising prevalence of multiple myeloma is another key factor that is expected to drive market growth during the forecast period. Multiple myeloma is a type of blood cancer that affects plasma cells in bone marrow and leads to an increase in tumor size and number over time, which can cause serious health problems such as kidney failure, infections, or even death if not treated properly. As there are limited treatment options available for this condition currently, the demand for nedaplatin API as a potential treatment option is high, thereby propelling market growth during the forecast period
Scope Of The Report
Report Attributes
Report Details
Report Title
Nedaplatin API Market Research Report
By Type
Purity ≥98%, Purity ≥99%
By Application
Lung Cancer, Esophageal Cancer, Bladder Cancer, Testicular Cancer, Ovarian Cancer, Cervical Cancer, Other
By Companies
Nanjing Hairun Pharmaceutical, Simcere, Qilu Pharma, Jilin Hengjin Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
189
Number of Tables & Figures
133
Customization Available
Yes, the report can be customized as per your need.
Global Nedaplatin API Market Report Segments:
The global Nedaplatin API market is segmented on the basis of:
Types
Purity ≥98%, Purity ≥99%
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Lung Cancer, Esophageal Cancer, Bladder Cancer, Testicular Cancer, Ovarian Cancer, Cervical Cancer, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Nanjing Hairun Pharmaceutical
- Simcere
- Qilu Pharma
- Jilin Hengjin Pharmaceutical
Highlights of The Nedaplatin API Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Purity ≥98%
- Purity ≥99%
- By Application:
- Lung Cancer
- Esophageal Cancer
- Bladder Cancer
- Testicular Cancer
- Ovarian Cancer
- Cervical Cancer
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Nedaplatin API Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Nedaplatin API is a prescription medication used to treat cancer. It is an alkylating agent that works by damaging the DNA of cancer cells.
Some of the major players in the nedaplatin api market are Nanjing Hairun Pharmaceutical, Simcere, Qilu Pharma, Jilin Hengjin Pharmaceutical.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Nedaplatin API Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Nedaplatin API Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Nedaplatin API Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Nedaplatin API Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Nedaplatin API Market Size & Forecast, 2020-2028
4.5.1 Nedaplatin API Market Size and Y-o-Y Growth
4.5.2 Nedaplatin API Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Purity ≥98%
5.2.2 Purity ≥99%
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Lung Cancer
6.2.2 Esophageal Cancer
6.2.3 Bladder Cancer
6.2.4 Testicular Cancer
6.2.5 Ovarian Cancer
6.2.6 Cervical Cancer
6.2.7 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Nedaplatin API Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Nedaplatin API Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Purity ≥98%
9.6.2 Purity ≥99%
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Lung Cancer
9.10.2 Esophageal Cancer
9.10.3 Bladder Cancer
9.10.4 Testicular Cancer
9.10.5 Ovarian Cancer
9.10.6 Cervical Cancer
9.10.7 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Purity ≥98%
10.6.2 Purity ≥99%
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Lung Cancer
10.10.2 Esophageal Cancer
10.10.3 Bladder Cancer
10.10.4 Testicular Cancer
10.10.5 Ovarian Cancer
10.10.6 Cervical Cancer
10.10.7 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Purity ≥98%
11.6.2 Purity ≥99%
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Lung Cancer
11.10.2 Esophageal Cancer
11.10.3 Bladder Cancer
11.10.4 Testicular Cancer
11.10.5 Ovarian Cancer
11.10.6 Cervical Cancer
11.10.7 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Purity ≥98%
12.6.2 Purity ≥99%
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Lung Cancer
12.10.2 Esophageal Cancer
12.10.3 Bladder Cancer
12.10.4 Testicular Cancer
12.10.5 Ovarian Cancer
12.10.6 Cervical Cancer
12.10.7 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Purity ≥98%
13.6.2 Purity ≥99%
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Lung Cancer
13.10.2 Esophageal Cancer
13.10.3 Bladder Cancer
13.10.4 Testicular Cancer
13.10.5 Ovarian Cancer
13.10.6 Cervical Cancer
13.10.7 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Nedaplatin API Market: Competitive Dashboard
14.2 Global Nedaplatin API Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Nanjing Hairun Pharmaceutical
14.3.2 Simcere
14.3.3 Qilu Pharma
14.3.4 Jilin Hengjin Pharmaceutical
